Niclas Högberg and William ‘Obi’ Greenman on Evolving Strategies in Massive Bleeding Management
Niclas Högberg, Sales Director at Cerus, reposted from William “Obi” Greenman on LinkedIn:
”MASSIVE BLEEDING – ARE WE DRIFTING APART IN STRATEGY?
In the U.S., 5-day Pathogen-Reduced Cryoprecipitated Fibrinogen Complex (PRCFC) is beginning to reshape massive transfusion practice.
As the study included concluded:
- “PRCFC is ready to dispense and provides an immediate source of fibrinogen in critically bleeding patients with significant reductions in TAT. There is an added benefit of reduced wastage.”
This evolution enables clinicians to act within minutes — moving beyond ratio-driven MTPs toward targeted, function-based hemostatic resuscitation.
Across Europe and the Nordics, focus has instead shifted toward Whole Blood (WB) for trauma and pre-hospital use.
While physiologically balanced, WB reintroduces challenges with traceability, shelf life, and pathogen safety — factors that SoHO and IVDR will soon regulate more tightly.
As Europe strengthens its blood preparedness and resilience, the key question is:
- Are we innovating forward — or reinventing the past for convenience?”
William “Obi” Greenman, Chairman and Chief Executive Officer at Cerus, shared on LinkedIn:
”The expansion of INTERCEPT Fibrinogen Complex use in large U.S. hospitals is really encouraging given the meaningful impact on immediate fibrinogen delivery in critically bleeding patients.
With >50% improvements in delivery time and reduced wastage, the efficiencies gained are real and the hospital transfusion service teams love the product and can focus their valuable time on other critical activities.”
Read the full article here.
Article: Pathogen-reduced cryoprecipitate: Early experiences and inventory management
Authors: C. B. Webb, A. Javanbakht, D. Hanna, S. G. Yates, R. Zhang, S. Afraz, R. Sarode

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera
